{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicy2suoq5orxxcccuyf2kk56ynuv3x6ajfm6l7r3xbgjxhqqnbn7y",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mn4txfn2p7w2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigvom4wetxuy3nf4j7vjtxhfca7tser6ixw72d6smowxievw7cboe"
    },
    "mimeType": "image/jpeg",
    "size": 84085
  },
  "path": "/2026/05/30/pancreatic-cancer-daraxonrasib-revolution-medicines-early-access-asco-2026/?utm_campaign=rss",
  "publishedAt": "2026-05-30T13:25:26.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Health",
    "Pharma",
    "ASCO",
    "biotech",
    "Cancer",
    "drug development",
    "FDA",
    "Pharmaceuticals",
    "STAT+"
  ],
  "textContent": "CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.",
  "title": "STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug",
  "updatedAt": "2026-05-30T13:42:12.000Z"
}